Skip to main content
Premium Trial:

Request an Annual Quote

DynaMetrix, Karolinka Institute Partner with NCI on cSNP Project

NEW YORK, Dec. 8 (GenomeWeb News) - DynaMetrix and the Karolinska Institute announced yesterday that they have partnered with the National Cancer Institute's Cancer Genome Anatomy Project to validate probable causal SNPs that underline differences in protein sequences between individuals.

 

According to DynaMetrix and the Karolinska Institute, these non-synonymous sequence differences - or ns-cSNPs - may be responsible for much of the variation between people in terms of disease risk and drug response.

 

The partners said are using DynaMetrix's DASH-2 genotyping and diagnostic systems to validate the ns-cSNPs in sets of 12, using black and white individuals. Thereafter, DASH will be used to determine allele frequencey distributions in large global populations.

 

Information generated by the project will be made publicly available on a Cancer Genome Anatomy Project website.

 

 

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.